Published in Scand J Rheumatol on January 01, 1978
The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum (1996) 6.88
Enzymatic iodination of polypeptides with 125I to high specific activity. Biochim Biophys Acta (1971) 6.67
Mortality in systemic lupus erythematosus. Arthritis Rheum (2006) 3.61
Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford) (2005) 3.42
EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis (2007) 3.32
Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus (2000) 2.81
Submillisecond kinetics of glutamate release from a sensory synapse. Neuron (1998) 2.70
The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum (1997) 2.49
Agarose gel electrophoresis. Scand J Clin Lab Invest Suppl (1972) 2.32
The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol (2000) 2.26
IgG subclasses in selective IgA deficiency: importance of IgG2-IgA deficiency. N Engl J Med (1981) 2.18
Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum (2007) 2.18
A case of hereditary angioneurotic oedema, successfully treated with epsilon-aminocaproic acid. Studies on C'1 esterase inhibitor, C'1 activation, plasminogen level and histamine metabolism. Clin Exp Immunol (1968) 2.17
Glomerular apoptotic nucleosomes are central target structures for nephritogenic antibodies in human SLE nephritis. Kidney Int (2007) 2.08
Different prooxidant levels stimulate growth, trigger apoptosis, or produce necrosis of insulin-secreting RINm5F cells. The role of intracellular polyamines. J Biol Chem (1994) 2.04
An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum (2005) 1.96
Screening for carcinoma of the prostate by digital rectal examination in a randomly selected population. BMJ (1990) 1.91
Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. Arthritis Care Res (Hoboken) (2010) 1.84
Sequential changes of plasma proteins after myocardial infarction. Scand J Clin Lab Invest Suppl (1972) 1.79
Estimating the incidence of systemic lupus erythematosus in a defined population using multiple sources of retrieval. Br J Rheumatol (1990) 1.70
Serum concentration of cystatin C, factor D and beta 2-microglobulin as a measure of glomerular filtration rate. Acta Med Scand (1985) 1.65
Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort. Arthritis Rheum (2008) 1.65
Activation of protein kinases and inhibition of protein phosphatases play a central role in the regulation of exocytosis in mouse pancreatic beta cells. Proc Natl Acad Sci U S A (1994) 1.59
Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine (Baltimore) (1989) 1.54
Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor. Mol Cell Endocrinol (2010) 1.53
Maternal smoking during pregnancy and the risk of childhood cancer. Lancet (1986) 1.51
Effects of sulindac and naproxen on prostaglandin excretion in patients with impaired renal function and rheumatoid arthritis. Am J Med (1990) 1.47
Nature of the tumor-associated determinant(s) of carcinoembryonic antigen. Proc Natl Acad Sci U S A (1975) 1.43
Systemic lupus erythematosus in an adult population in southern Sweden: incidence, prevalence and validity of ARA revised classification criteria. Br J Rheumatol (1985) 1.38
Changes in hip fracture epidemiology: redistribution between ages, genders and fracture types. Osteoporos Int (2002) 1.38
Complement components, complement activation, and acute phase response in systemic lupus erythematosus. Int Arch Allergy Appl Immunol (1984) 1.36
Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study. Arthritis Rheum (2008) 1.34
Circulating anti-elastase in systemic lupus erythematosus. Lancet (1989) 1.33
Complement deficiency and disease: an update. Mol Immunol (2006) 1.33
Immunoglobulins of cerebrospinal fluid in syphilis. Br J Vener Dis (1969) 1.31
Conversion of the fourth complement component studied by crossed immunoelectrophoresis. Clin Exp Immunol (1973) 1.30
Inhibition of phosphatases and increased Ca2+ channel activity by inositol hexakisphosphate. Science (1997) 1.30
A susceptibility locus for human systemic lupus erythematosus (hSLE1) on chromosome 2q. J Autoimmun (2000) 1.29
Activation of C'1 to C'1 esterase on gel filtration on Sephadex G-200. Studies on normal human serum, euglobulin and hereditary angioneurotic edema serum. Acta Pathol Microbiol Scand (1966) 1.29
Inter-observer variation in assessment of the prostate by digital rectal examination. Br J Urol (1993) 1.29
Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis (2009) 1.27
Autonomic nerve function in rheumatoid arthritis of varying severity. Scand J Rheumatol (1983) 1.25
Inability of a highly purified streptokinase preparation to inactivate complement in serum. Acta Pathol Microbiol Scand (1965) 1.25
Palmoplantar pustulosis and sternocostoclavicular arthro-osteitis. Ann Rheum Dis (1988) 1.25
Studies of the third component of complement in synovial fluid from arthritic patients. II. Conversion and its relation to total complement. Clin Exp Immunol (1970) 1.24
Anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum (1987) 1.24
Incidence studies of systemic lupus erythematosus in Southern Sweden: increasing age, decreasing frequency of renal manifestations and good prognosis. J Rheumatol (2000) 1.23
Enzymatic and immunochemical estimation of C'1 esterase inhibitor in sera from patients with hereditary angioneurotic edema. Scand J Clin Lab Invest (1969) 1.21
Autoantibodies against neutrophil cytoplasm components in systemic lupus erythematosus and in hydralazine-induced lupus. Clin Exp Immunol (1990) 1.20
Non-Hodgkin's lymphoma in systemic lupus erythematosus. Ann Rheum Dis (2005) 1.19
Quantitative immunochemical determination of lysoqyme (muramidase) in serum and urine. Scand J Clin Lab Invest (1971) 1.17
Risk factors for developing systemic lupus erythematosus: a case-control study in southern Sweden. Rheumatology (Oxford) (2002) 1.16
Changes in plasma high density lipoproteins in chronic male alcoholics during and after abuse. Scand J Clin Lab Invest (1978) 1.16
Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis. Ann Rheum Dis (2006) 1.15
Complement factors in gingival crevice material from healthy and inflamed gingiva in humans. J Periodontal Res (1975) 1.15
An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA. Ann Rheum Dis (2010) 1.12
Nerve palsy after knee arthroplasty in patients with rheumatoid arthritis. Scand J Rheumatol (1983) 1.12
Screening for deficiencies in the classical and alternative pathways of complement by hemolysis in gel. Acta Pathol Microbiol Scand C (1981) 1.11
Studies of the third component of complement in synovial fluid from arthritic patients. Clin Exp Immunol (1970) 1.10
Isolation of crystalline lactoferrin from human milk. Acta Chem Scand (1969) 1.08
C1 subcomponent conplexes in normal and pathological sera studied by crossed immunoelectrophoresis. Acta Pathol Microbiol Scand C (1976) 1.08
Polyarteritis nodosa when applying the Chapel Hill nomenclature--a descriptive study on ten patients. Rheumatology (Oxford) (2006) 1.08
Liver function in some common rheumatic disorders. Scand J Rheumatol (1980) 1.08
C1 inactivator protein complexed with albumin in plasma from a patient with angioneurotic edema. Eur J Immunol (1971) 1.08
Complement activating rheumatoid factors in rheumatoid arthritis studied by haemolysis in gel: relation to antibody class and response to treatment with podophyllotoxin derivatives. Clin Exp Rheumatol (1985) 1.07
Complement classical pathway components are all important in clearance of apoptotic and secondary necrotic cells. Clin Exp Immunol (2009) 1.07
Clinical and serological features of severe vasculitis in rheumatoid arthritis: prognostic implications. Ann Rheum Dis (1987) 1.07
Association between SLE nephritis and polymorphic variants of the CRP and FcgammaRIIIa genes. Rheumatology (Oxford) (2007) 1.06
Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care Res (Hoboken) (2012) 1.06
Reduction and proteolytic degradation of immunoglobulin A from human colostrum. Acta Chem Scand (1966) 1.06
Outcome of incomplete systemic lupus erythematosus after 10 years. Lupus (2004) 1.06
Increased monocyte transcription of the proteinase 3 gene in small vessel vasculitis. Clin Exp Immunol (2005) 1.06
Protein kinase C modulates the insulin secretory process by maintaining a proper function of the beta-cell voltage-activated Ca2+ channels. J Biol Chem (1994) 1.05
Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden. Rheumatology (Oxford) (2007) 1.05
Predictors of extra-articular manifestations in rheumatoid arthritis. Scand J Rheumatol (2000) 1.04
Effect of trypsin on complement components in normal human serum. Acta Pathol Microbiol Scand (1968) 1.04
Autoantibodies against C1q: view on clinical relevance and pathogenic role. Clin Exp Immunol (1999) 1.03
Interaction of streptococci with the Fc fragment of IgG. Acta Pathol Microbiol Scand C (1976) 1.02
Sequential studies of complement activation in systemic lupus erythematosus. Scand J Rheumatol (1985) 1.02
Race/ethnicity and cancer occurrence in systemic lupus erythematosus. Arthritis Rheum (2005) 1.02
Short-term outcome of neuropsychiatric events in systemic lupus erythematosus upon enrollment into an international inception cohort study. Arthritis Rheum (2008) 1.01
Maternal smoking during pregnancy and risk of childhood cancer. Lancet (1986) 1.00
Autoantibodies in systemic lupus erythematosus: comparison of historical and current assessment of seropositivity. Lupus (2011) 1.00
Low diagnostic and predictive value of anti-dsDNA antibodies in unselected patients with recent onset of rheumatic symptoms: results from a long-term follow-up Scandinavian multicentre study. Scand J Rheumatol (2013) 0.98
Hereditary angioneurotic oedema in three families. Symptomatic heterogeneity, complement analysis and therapeutic trials. Acta Med Scand (1972) 0.98
Formation of complexes composed of C1r, C1s, and C1 inactivator in human serum on activation of C1. Acta Pathol Microbiol Scand C (1978) 0.98
IgG3 deficiency: common in obstructive lung disease. Hereditary in families with immunodeficiency and autoimmune disease. Monogr Allergy (1986) 0.97
Screening for carcinoma of the prostate in a randomly selected population using duplicate digital rectal examination. Acta Oncol (1991) 0.97
Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort. Lupus (2007) 0.97
Screening for carcinoma of the prostate in a randomly selected population. Recent Results Cancer Res (1993) 0.97
Association of the Charlson comorbidity index with mortality in systemic lupus erythematosus. Arthritis Care Res (Hoboken) (2011) 0.97
Serum immunoglobulin levels in syphilis. Acta Derm Venereol (1968) 0.96
Homozygous deficiency of C4 in a child with a lupus erythematosus syndrome. Clin Genet (1982) 0.96
EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis. Ann Rheum Dis (2004) 0.94
Abnormal mechanical properties of larger arteries in postmenopausal women with systemic lupus erythematosus. Lupus (2004) 0.94
Disorders of serum alpha-lipoproteins after alcoholic intoxication. Scand J Clin Lab Invest (1969) 0.94
Systemic lupus erythematosus and infection: a controlled and prospective study including an epidemiological group. Q J Med (1985) 0.94
Clinical inconsistency, benign course and normal employment rates in unselected systemic lupus erythematosus. Clin Exp Rheumatol (1986) 0.94
A novel assay for neutrophil clustering activity of human sera: relation to disease activity and neutropenia in systemic lupus erythematosus. Ann Rheum Dis (1990) 0.93
ACR classification criteria for systemic lupus erythematosus: complement components. Lupus (2004) 0.93